نتایج جستجو برای: pemetrexed

تعداد نتایج: 3190  

Journal: :Indian Journal of Pharmaceutical Sciences 2022

We attempt to study the short-term efficacy of tislelizumab+carboplatin/cisplatin+pemetrexed in advanced lung adenocarcinoma and its effect on tumor markers. Retrospectively analyzed clinical data 68 patients admitted our hospital from May 2019 June 2021 divided them into control group (n=34) (n=34). Treated with carboplatin or cisplatin+pemetrexed, while treated tislelizumab+carboplatin cispla...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2006
Christian Dittrich Lubos Petruzelka Pavel Vodvarka Margit Gneist Filip Janku Tamara Kysela Allen Melemed Jane Latz Lorinda Simms Kurt Krejcy

PURPOSE Determine the maximum tolerated dose (MTD) of pemetrexed and cyclophosphamide combination therapy for patients with locally advanced or metastatic breast cancer. EXPERIMENTAL DESIGN Patients with locally advanced or metastatic breast cancer and WHO performance status 0 to 2 were eligible. Pemetrexed (range, 400-2,400 mg/m(2)) was administered on day 1 of a 21-day schedule followed by ...

Journal: :Anticancer research 2012
Tetsuo Shimizu Yoko Nakanishi Yoshiko Nakagawa Ichiro Tsujino Noriaki Takahashi Norimichi Nemoto Shu Hashimoto

BACKGROUND Pemetrexed inhibits three key folate enzymes: thymidylate synthetase (TYMS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT). The relationship between the clinical efficacy of pemetrexed and the expression of folate enzymes in lung cancer cells is unknown. The purpose of this study was to determine whether TYMS, DHFR, and GARFT expression affe...

2016
Young Saing Kim Eun Kyung Cho Hyun Sun Woo Junshik Hong Hee Kyung Ahn Inkeun Park Sun Jin Sym Sun Young Kyung Shin Myung Kang Jeong-Woong Park Sung Hwan Jeong Jinny Park Jae Hoon Lee Dong Bok Shin

PURPOSE This study aimed to evaluate the efficacy and safety of pemetrexed versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy. MATERIALS AND METHODS Patients with advanced (stage IIIB or IV) or recurrent NSCLC were randomly assigned to receive either 500 mg/m² of pemetrexed intravenously every 3 weeks or gefitinib 250 mg/day oral...

Journal: :Molecular pharmacology 2005
Elisa Giovannetti Valentina Mey Sara Nannizzi Giuseppe Pasqualetti Luca Marini Mario Del Tacca Romano Danesi

Gemcitabine and pemetrexed are effective agents in the treatment of non-small-cell lung cancer (NSCLC), and the present study investigates cellular and genetic aspects of their interaction against A549, Calu-1, and Calu-6 cells. Cells were treated with pemetrexed and gemcitabine, and their interaction was assessed using the combination index. The role of drug metabolism in gemcitabine cytotoxic...

2017
Vijay Maruti Patil Vanita Noronha Amit Joshi Anuradha Bharat Choughule Atanu Bhattacharjee Rajiv Kumar Supriya Goud Sucheta More Anant Ramaswamy Ashay Karpe Nikhil Pande Arun Chandrasekharan Alok Goel Vikas Talreja Abhishek Mahajan Amit Janu Nilendu Purandare Kumar Prabhash

OBJECTIVE Oral tyrosine kinase inhibitor has been shown to prolong progression-free survival (PFS) in estimated glomerular filtration rate (EGFR) mutation positive adenocarcinoma; however, the comparator arm has not included the current standard adenocarcinoma regimen (pemetrexed carboplatin induction followed by maintenance pemetrexed) and patients from Indian subcontinent. Hence, this study w...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2015
Maria M Posada James A Bacon Karen B Schneck Rommel G Tirona Richard B Kim J William Higgins Y Anne Pak Stephen D Hall Kathleen M Hillgren

Pemetrexed, an anionic anticancer drug with a narrow therapeutic index, is eliminated mainly by active renal tubular secretion. The in vitro to in vivo extrapolation approach used in this work was developed to predict possible drug-drug interactions (DDIs) that may occur after coadministration of pemetrexed and nonsteroidal anti-inflammatory drugs (NSAIDs), and it included in vitro assays, risk...

Journal: :Molecular cancer therapeutics 2006
Shrikanta Chattopadhyay Rongbao Zhao Sergey A Krupenko Natalia Krupenko I David Goldman

Pemetrexed, a new generation antifolate recently approved for the treatment of mesothelioma and non-small cell lung cancer, is an excellent substrate for the reduced folate carrier (RFC). To explore the carrier's effect on pemetrexed activity, RFC was inactivated in HCT-15 colon cancer cells by mutagenesis and PT632 selective pressure. A clone (PT1) was obtained with a glycine to arginine subst...

Journal: :Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 2010
S Villanueva-Herraiz M P Ortega-García C Camps-Herrero P Blasco-Segura

OBJECTIVE To study the effectiveness and safety of pemetrexed in non-small cell lung cancer. METHOD Retrospective study (March 2006-May 2008) of pemetrexed use. Information was obtained from the Access database belonging to the Pharmacy and Oncology Departments, the registry of external consultations and clinical histories. Data were analysed using SPSS software version 12.0. Quantitative var...

2015
Maria M. Posada James A. Bacon Karen B. Schneck Rommel G. Tirona Richard B. Kim J. William Higgins Y. Anne Pak Stephen D. Hall Kathleen M. Hillgren

Pemetrexed, an anionic anticancer drug with a narrow therapeutic index, is eliminated mainly by active renal tubular secretion. The in vitro to in vivo extrapolation approach used in this work was developed to predict possible drug-drug interactions (DDIs) that may occur after coadministration of pemetrexed and nonsteroidal anti-inflammatory drugs (NSAIDs), and it included in vitro assays, risk...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید